Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults
Shots:
- Eli Lilly reported topline data from P-IIIb (SURMOUNT-5) study assessing safety & efficacy of Zepbound (10 or 15mg) vs Wegovy (1.7or 2.4mg) in obese adults (n=751) with hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease & not having diabetes
- Study depicted 47% greater weight loss than Wegovy, with an average loss of 20.2% vs 13.7% at 72wks. and 31.6% vs 16.1% of Zepbound users achieved ≥25% weight loss (2EP). Both drugs showed similar safety profiles, with mostly mild to moderate gastrointestinal AEs
- Lilly will further analyze results from SURMOUNT-5 trial and will publish in a journal and conference during 2025
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
